This is a major milestone met, and at the top end of expectations. It is a significant requirement to unlocking the very large profits that Thunderbird has the potential of producing. It is a major de-risking event.
the remaining important piece of the puzzle before FID is the approx $160mil of commercial funding.
Don't be surprised to see this drop imminently. It's most likely that NAIF and commercial funding have been managed in parallel with the commercial funding contingent on NAIF and vice versa.
This quantum of funding should ensure that no further capital raise is required (except possibly a small $5mil raise, hopefully via a rights issue, as a top up to working capital for the next few years).
Another great result in my books and we should see the share price respond accordingly. Remember the price target just issued by Bridge Street is $2.00 per share.
all the best
- Forums
- ASX - By Stock
- SFX
- Ann: NAIF Approves $160m Loan for Thunderbird Project
SFX
sheffield resources limited
Add to My Watchlist
8.57%
!
19.0¢

Ann: NAIF Approves $160m Loan for Thunderbird Project, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
19.0¢ |
Change
0.015(8.57%) |
Mkt cap ! $75.01M |
Open | High | Low | Value | Volume |
19.5¢ | 19.5¢ | 18.0¢ | $22.45K | 119.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 69125 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 13115 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 69125 | 0.180 |
1 | 850 | 0.175 |
2 | 285138 | 0.170 |
2 | 293340 | 0.160 |
1 | 35000 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 13115 | 1 |
0.200 | 42155 | 2 |
0.225 | 13000 | 1 |
0.230 | 196888 | 1 |
0.240 | 20000 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
SFX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online